Direkt zum Inhalt
Merck
  • Modest hypoxia significantly reduces triglyceride content and lipid droplet size in 3T3-L1 adipocytes.

Modest hypoxia significantly reduces triglyceride content and lipid droplet size in 3T3-L1 adipocytes.

Biochemical and biophysical research communications (2013-09-18)
Takeshi Hashimoto, Takumi Yokokawa, Yuriko Endo, Nobumasa Iwanaka, Kazuhiko Higashida, Sadayoshi Taguchi
ZUSAMMENFASSUNG

A previous study has demonstrated that endurance training under hypoxia results in a greater reduction in body fat mass compared to exercise under normoxia. However, the cellular and molecular mechanisms that underlie this hypoxia-mediated reduction in fat mass remain uncertain. Here, we examine the effects of modest hypoxia on adipocyte function. Differentiated 3T3-L1 adipocytes were incubated at 5% O2 for 1 week (long-term hypoxia, HL) or one day (short-term hypoxia, HS) and compared with a normoxia control (NC). HL, but not HS, resulted in a significant reduction in lipid droplet size and triglyceride content (by 50%) compared to NC (p<0.01). As estimated by glycerol release, isoproterenol-induced lipolysis was significantly lowered by hypoxia, whereas the release of free fatty acids under the basal condition was prominently enhanced with HL compared to NC or HS (p<0.01). Lipolysis-associated proteins, such as perilipin 1 and hormone-sensitive lipase, were unchanged, whereas adipose triglyceride lipase and its activator protein CGI-58 were decreased with HL in comparison to NC. Interestingly, such lipogenic proteins as fatty acid synthase, lipin-1, and peroxisome proliferator-activated receptor gamma were decreased. Furthermore, the uptake of glucose, the major precursor of 3-glycerol phosphate for triglyceride synthesis, was significantly reduced in HL compared to NC or HS (p<0.01). We conclude that hypoxia has a direct impact on reducing the triglyceride content and lipid droplet size via decreased glucose uptake and lipogenic protein expression and increased basal lipolysis. Such an hypoxia-induced decrease in lipogenesis may be an attractive therapeutic target against lipid-associated metabolic diseases.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Esterase aus Schweineleber, lyophilized powder, ≥15 units/mg solid
Sigma-Aldrich
Cholesterin-Esterase aus Pseudomonas fluorescens, lyophilized powder, ≥10,000 units/g protein
Sigma-Aldrich
Cholesterin-Esterase aus Rinderpankreas, lyophilized powder, ≥200 units/g protein
Sigma-Aldrich
Esterase aus Schweineleber, ammonium sulfate suspension, ≥150 units/mg protein (biuret)
Sigma-Aldrich
Cholesterinesterase aus Schweinepankreas, lyophilized, powder, white, ~35 U/mg
Sigma-Aldrich
Esterase aus Bacillus subtilis, recombinant, expressed in E. coli, ≥10 U/mg
Sigma-Aldrich
Esterase aus Schweineleber, lyophilized, powder, slightly beige, ≥50 U/mg
Sigma-Aldrich
Cholesterin-Esterase aus Pseudomonas sp., lyophilized powder, ≥200,000 units/g protein
Sigma-Aldrich
Carboxylesterase 2 human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Carboxylesterase 1 isoform b human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Esterase aus Kaninchenleber, lyophilized powder, ≥30 units/mg protein
Sigma-Aldrich
Esterase aus Bacillus stearothermophilus, recombinant, expressed in E. coli, ≥4.0 U/mg
Sigma-Aldrich
Esterase aus Bacillus stearothermophilus, ≥0.2 U/mg
Sigma-Aldrich
Carboxylesterase 2 human, recombinant, expressed in mouse NSO cells, ≥95% (SDS-PAGE)
Sigma-Aldrich
Carboxylesterase 1 isoform c human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Esterase Pseudomonas fluorescens, rekombinant aus E. coli, ≥4 U/mg
Sigma-Aldrich
Esteraseisoenzym-1 aus Schweineleber, rekombinant, recombinant, expressed in E. coli, ≥30.0 U/g